Appraising today's role of bivalirudin and glycoprotein IIb/IIIa inhibitors in the modern era of antiplatelet pharmacotherapy

Session comprising selected EuroPCR 2015 abstract submissions

Chairperson: S.B. King III
Panellists: M. Angioi, J.F. Tanguay

Presentations available when logged in:

  • Randomised evaluation of intralesion versus intracoronary abciximab and aspiration thrombectomy in patients with STEMI: the COCKTAIL II trial
  • Post-procedural bivalirudin infusion duration and acute stent thrombosis rates from a large United Kingdom primary angioplasty programme: how long...
  • Clinical outcomes between eptifibatide and abciximab remain similar during primary PCI for STEMI
  • Meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitor in patients with ACS
  • Intracoronary-bolus only versus intracoronary-bolus plus infusion administration of glycoprotein IIb/IIIa inhibitors in patients with STEMI undergo...